Clinical Trial Results - Evorpacept demonstrated a 65.0% objective response rate (ORR) in patients with retained HER2+ and CD47-high gastric cancer, compared to 26.1% for the control group[4] - The median duration of response (DOR) for evorpacept plus trastuzumab, ramucirumab, and paclitaxel was 25.5 months, significantly longer than the 8.4 months for the control group[4] - Progression-free survival (PFS) for the evorpacept combination was 18.4 months versus 7.0 months for the control, with a hazard ratio (HR) of 0.39[4] - The Phase 2 ASPEN-09-Breast Cancer trial is on track for first patient in (FPI) in Q4 2025, with interim data expected in Q3 2026[4] - The Phase 1 trial for ALX2004 is currently enrolling patients and is expected to deliver initial safety data in the first half of 2026[4] Financial Performance - Cash, cash equivalents, and investments as of September 30, 2025, were $66.5 million, sufficient to fund operations into Q1 2027[11] - Research and development (R&D) expenses for Q3 2025 were $17.4 million, a decrease of $9.0 million from the prior year[11] - General and administrative (G&A) expenses for Q3 2025 were $5.1 million, down from $6.1 million in the prior year[11] - GAAP net loss for Q3 2025 was ($22.1) million, or ($0.41) per share, compared to a net loss of ($30.7) million, or ($0.58) per share, in Q3 2024[11] - For the three months ended September 30, 2025, the total operating expenses were $22,532,000, a decrease of 30.8% compared to $32,567,000 for the same period in 2024[15] - The net loss for the three months ended September 30, 2025, was $22,144,000, which is a reduction of 27.8% from the net loss of $30,707,000 in the prior year[15] - The company reported a non-GAAP net loss of $19,551,000 for the three months ended September 30, 2025, compared to a non-GAAP net loss of $23,689,000 for the same period in 2024, reflecting a 17.9% improvement[19] - Cash, cash equivalents, and investments decreased to $66,464,000 as of September 30, 2025, down from $131,281,000 at the end of 2024, indicating a decline of 49.3%[17] - Total assets as of September 30, 2025, were $82,723,000, a decrease of 44.0% from $147,775,000 on December 31, 2024[17] - The accumulated deficit increased to $699,969,000 as of September 30, 2025, compared to $621,122,000 at the end of 2024, representing an increase of 12.6%[17] - Total stockholders' equity decreased to $44,800,000 as of September 30, 2025, down from $113,618,000 at the end of 2024, a decline of 60.6%[17] - Research and development expenses for the three months ended September 30, 2025, were $17,441,000, a decrease of 34.1% from $26,471,000 in the same period of 2024[15] - Interest income for the three months ended September 30, 2025, was $802,000, compared to $2,303,000 in the same period of 2024, reflecting a decrease of 65.2%[15] - The weighted-average shares of common stock used to compute net loss per share increased to 53,577,066 for the three months ended September 30, 2025, compared to 52,693,878 for the same period in 2024, an increase of 1.7%[15] Management Changes - Barbara Klencke, M.D., has been appointed as Chief Medical Officer, bringing over 30 years of experience in oncology drug development[4]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Global Partners LP Global Partners LP Chief Financial Officer Chief Legal Officer and Secretary (781) 894-8800 (781) 894-8800 Global Partners Reports Third-Quarter 2025 Financial Results Waltham, Mass., November 7, 2025 – Global Partners LP (NYSE: GLP) ("Global" or the "Partnership") today reported financial results for the third quarter ended September 30, 2025. CEO Commentary "Global performed well in the third quarter, consisten ...

TREDEGAR REPORTS THIRD QUARTER 2025 RESULTS RICHMOND, VA--(BUSINESS WIRE)--November 7, 2025--Tredegar Corporation (NYSE:TG, also the "Company" or "Tredegar") today reported third quarter financial results for the period ended September 30, 2025. Third quarter 2025 net income (loss) from continuing operations was $7.1 million ($0.20 per diluted share) compared to $(3.4) million ((0.10) per diluted share) in the third quarter of 2024. Net income (loss) from ongoing operations, which excludes special items, wa ...

Membership Growth - As of September 30, 2025, Clover Health has 109,226 members, an increase from 81,110 members in the same period of 2024, representing a growth of approximately 34.6%[111] Financial Performance - Gross premiums earned for the three months ended September 30, 2025, were $479,220,000, compared to $322,676,000 for the same period in 2024, reflecting a year-over-year increase of 48.5%[117] - Adjusted EBITDA for the nine months ended September 30, 2025, was $45,028,000, down from $62,292,000 in the same period of 2024, a decrease of approximately 27.7%[117] - Adjusted EBITDA for the three months ended September 30, 2025, was $2.1 million, compared to $19.3 million in 2024[134] - Total revenues increased by $165.7 million, or 50.1%, to $496.7 million for the three months ended September 30, 2025, compared to the same period in 2024[139] - Total revenues for the nine months ended September 30, 2025, were $1,436.6 million, reflecting a $402.4 million, or 38.9% increase compared to the previous year[146] Expense Management - The benefits expense ratio, gross, for the three months ended September 30, 2025, was 93.5%, compared to 82.8% in the same period of 2024, indicating a deterioration in expense management[117] - The normalized benefits expense ratio, gross, for the three months ended September 30, 2025, was 92.4%, compared to 85.4% in the same period of 2024, indicating increased costs relative to premiums[117] - General and administrative expenses increased by $13.8 million, or 39%, to $49.0 million for the three months ended September 30, 2025, compared to the same period in 2024[144] - Total operating expenses increased by $414.3 million, or 39.1%, to $1,472.8 million, with significant contributions from net medical claims and general administrative expenses[146] Claims and Premiums - Net medical claims incurred increased by $173.7 million, or 70%, to $423.5 million for the three months ended September 30, 2025, compared to the same period in 2024[142] - Premiums earned, net rose by $156.5 million, or 49%, to $479.1 million for the three months ended September 30, 2025, driven by a 35% growth in average members[140] - Net medical claims incurred increased by $391.6 million, or 51%, to $1,154.9 million, influenced by a 32% growth in average members and changes from the Inflation Reduction Act[149] Net Income and Loss - Adjusted net income from continuing operations for the three months ended September 30, 2025, was $1,705,000, compared to $18,924,000 in the same period of 2024, a decline of approximately 91%[117] - Net loss from continuing operations was $24.4 million for the three months ended September 30, 2025, compared to a loss of $8.8 million in 2024, representing a 177.5% increase in loss[139] - Net loss for the nine months ended September 30, 2025, was $36.2 million, a 73.2% increase from the net loss of $20.9 million in the prior year[146] Cash Flow - Cash and cash equivalents for the company were $395.9 million as of September 30, 2025, down from $437.6 million at the end of 2024[154] - Net cash provided by operating activities from continuing operations was $1.2 million for the nine months ended September 30, 2025, compared to $129.5 million in the prior year[159] - Net cash provided by investing activities was $39.1 million for the nine months ended September 30, 2025, primarily from sales and maturities of investment securities[164] - Net cash used in financing activities was $44.8 million for the nine months ended September 30, 2025, mainly due to stock-based compensation and share repurchases[166] Ratings and Technology - The company’s PPO Medicare Advantage plans received a CMS Star rating of 3.5 for 2026, a decrease from previous ratings, while the HMO MA plan rating increased to 4.0 stars[112] - The company’s proprietary software platform, Clover Assistant, is designed to enhance chronic disease management and improve clinical decision-making for physicians[110] - Clover Health's strategy focuses on expanding its physician networks and leveraging technology to improve care for Medicare beneficiaries[110]

Financial Performance - Net income from continuing operations for Q3 2025 was $7.1 million ($0.20 per diluted share), compared to a loss of $3.4 million ($0.10 per diluted share) in Q3 2024 [101]. - For the first nine months of 2025, net income from continuing operations was $9.6 million, compared to $8.4 million in the same period of 2024 [115]. - Net sales for the three months ended September 30, 2025, increased to $194.9 million, up 33.5% from $146.1 million in the same period of 2024 [147]. - Net sales in the first nine months of 2025 increased by 27.2% to $444.5 million, driven by higher sales volume and the pass-through of increased metal costs [126]. - Net sales for PE Films in Q3 2025 increased by 4.0% to $25.883 million compared to Q3 2024, driven by a 10.9% increase in sales volume in surface protection films [136]. - Net sales in the first nine months of 2025 decreased by 3.5% to $76.017 million compared to the same period in 2024, attributed to a decrease in sales volume in surface protection and overwrap films [140]. Operational Metrics - EBITDA from ongoing operations for Aluminum Extrusions was $16.8 million in Q3 2025, up from $6.2 million in Q3 2024, with sales volume increasing to 41.3 million pounds from 34.6 million pounds [102]. - EBITDA from ongoing operations for PE Films was $7.2 million in Q3 2025, compared to $5.9 million in Q3 2024, with sales volume slightly increasing to 9.7 million pounds from 9.6 million pounds [102]. - EBITDA from ongoing operations increased by $10.6 million in the third quarter of 2025 compared to the same quarter in 2024 [131]. - EBITDA from ongoing operations in the first nine months of 2025 increased by $3.6 million compared to the same period in 2024, driven by a $12.7 million increase in contribution margin [132]. - EBITDA from ongoing operations for PE Films in Q3 2025 increased by 22.9% to $7.221 million compared to Q3 2024 [135]. Cost and Expense Management - Consolidated gross profit margin increased to 16.0% in Q3 2025 from 12.4% in Q3 2024, driven by higher volume and favorable pricing [106]. - Selling, general and administrative (SG&A) expenses as a percentage of sales decreased to 10.5% in Q3 2025 from 13.0% in Q3 2024, while SG&A spending increased by 8.3% [107]. - Interest expense decreased to $0.8 million in Q3 2025 from $1.2 million in Q3 2024, primarily due to lower average total debt and interest rates [108]. - Corporate expenses increased by $4.9 million in the first nine months of 2025 compared to the same period in 2024, primarily due to higher professional fees and employee-related compensation [143]. Taxation and Interest - The effective tax rate for Q3 2025 was 22.1%, compared to (32.3)% in Q3 2024, influenced by taxable discrete items [109]. - The effective tax rate for income taxes from continuing operations was 27.1% in the first nine months of 2025, slightly down from 27.5% in the prior year [119]. Debt and Financing - Average total outstanding debt decreased to $60.0 million in the first nine months of 2025 from $128.6 million in the same period of 2024, with the average interest rate dropping to 6.8% from 9.1% [123]. - Net cash used in financing activities was $13.7 million in the first nine months of 2025, compared to $3.6 million in the same period of 2024, primarily due to lower debt borrowings [153]. - The Company entered into Amendment No. 5 to the ABL Facility, extending the maturity date to May 6, 2030, with $72.5 million available to borrow as of September 30, 2025 [156]. - The Company has a $125 million senior secured asset-based revolving credit facility, with $72.5 million available to borrow as of September 30, 2025 [156]. Cash Flow and Liquidity - Net cash provided by operating activities was $17.3 million in the first nine months of 2025, compared to $6.1 million in the same period of 2024, driven by higher segment EBITDA [151]. - As of September 30, 2025, the Company had cash and cash equivalents of $13.3 million, including $2.0 million held outside the U.S. [154]. - The Company believes existing cash flow and borrowing availability will satisfy short-term cash requirements for at least the next 12 months [164]. Inventory and Receivables - Accounts and other receivables increased by $23.1 million (35.7%), with DSO for Aluminum Extrusions at approximately 44.2 days [155]. - Inventories rose by $10.6 million (20.7%), with DIO for Aluminum Extrusions at approximately 48.7 days [155]. - Accounts payable increased by $14.5 million (22.5%), with DPO at approximately 45.8 days for the 12 months ended September 30, 2025 [155]. Capital Expenditures - Capital expenditures for Bonnell Aluminum are projected to be $17 million in 2025, including $5 million for productivity projects [134]. - Projected capital expenditures for PE Films are $2 million in 2025, including $1 million for productivity projects [142]. - Projected depreciation expense for Bonnell Aluminum is $15 million in 2025, while amortization expense is projected to be $2 million [134].

Financial Performance - For Q3 2025, Conduent reported a net loss of $46 million, compared to a net income of $123 million in Q3 2024, representing a significant decline[14] - Comprehensive loss for Q3 2025 was $50 million, down from a comprehensive income of $137 million in the same quarter last year[14] - Conduent reported a net loss of $46 million for the three months ended September 30, 2025, compared to a net income of $123 million for the same period in 2024, representing a decline of 137%[22] - Total comprehensive loss for the three months ended September 30, 2025, was $50 million, compared to a total comprehensive income of $137 million for the same period in 2024[22] - The company reported an income (loss) before income taxes of $(38) million for Q3 2025, compared to $159 million in Q3 2024[50] - Basic net earnings per share for Q3 2025 were $(0.30), down from $0.75 in Q3 2024, indicating a negative trend in profitability[106] Assets and Liabilities - Total assets decreased to $2.5 billion as of September 30, 2025, down from $2.6 billion at the end of 2024[17] - Cash and cash equivalents fell to $248 million, a decrease of $118 million from $366 million at the end of 2024[17] - Long-term debt increased to $697 million, up from $615 million at the end of 2024, indicating rising financial leverage[17] - The balance of retained earnings (deficit) increased to $(2,577) million as of September 30, 2025, from $(2,418) million as of September 30, 2024, indicating a deterioration in retained earnings[22] - The total other current assets decreased slightly to $258 million as of September 30, 2025, from $261 million at the end of 2024[108] - Total other current liabilities remained stable at $289 million as of September 30, 2025, compared to $290 million at the end of 2024[108] Revenue and Segments - Total consolidated revenue for Q3 2025 was $767 million, a decrease of 5% from $807 million in Q3 2024[38] - Commercial segment revenue decreased to $367 million in Q3 2025 from $385 million in Q3 2024, representing a decline of 4.7%[38] - Government segment revenue decreased to $238 million in Q3 2025 from $255 million in Q3 2024, a decline of 6.7%[38] - Transportation segment revenue increased to $162 million in Q3 2025 from $141 million in Q3 2024, marking a growth of 14.9%[38] - For the nine months ended September 30, 2025, total revenue was $2.272 billion, down from $2.556 billion in the same period of 2024, a decrease of 11.1%[38] Cash Flow and Operating Activities - Net cash used in operating activities for the nine months ended September 30, 2025, was $112 million, compared to a net cash used of $91 million in the same period of 2024[19] - Proceeds from divestitures amounted to $53 million in the nine months ended September 30, 2025, significantly lower than $823 million in the same period of 2024[19] Equity and Stock - The company had treasury stock purchases amounting to $13 million in Q3 2025, compared to $14 million in Q3 2024[22] - Conduent's additional paid-in capital increased to $3,964 million as of September 30, 2025, up from $3,952 million as of September 30, 2024[22] - The company had a total equity of $717 million as of September 30, 2025, down from $881 million as of September 30, 2024[22] - The Company issued 120,000 shares of Series A convertible perpetual preferred stock with a liquidation preference of $120 million, earning quarterly cash dividends at a rate of 8% per year[105] - The Company has not declared any common stock dividends during the periods presented, indicating a focus on retaining earnings[106] Restructuring and Costs - The company incurred restructuring costs totaling $24 million for the nine months ended September 30, 2025, compared to $21 million for the same period in 2024[64] - The company has ongoing restructuring programs aimed at reducing costs and improving productivity, with potential future provisions for new initiatives[62] Debt and Financial Obligations - As of September 30, 2025, the Company had $134 million in outstanding borrowings under its Revolving Credit Facility and utilized $25 million for letters of credit[77] - The Company had a remaining unused capacity of $198 million under the Revolving Credit Facility and $11 million under the Performance Letter of Credit Facility as of September 30, 2025[77] - The Company was in compliance with all debt covenants, including a consolidated first lien net leverage ratio not exceeding 4.50 to 1.00 and a fixed charge coverage ratio of at least 2.50 to 1.00[79] - The Company recognized a loss on extinguishment of debt of $1 million for the three months ended September 30, 2025, related to the voluntary repayment of Term Loan A[78] Market Conditions and Challenges - The company has faced challenges related to geopolitical events and macroeconomic conditions, impacting its operational performance and market competitiveness[7] Other Financial Information - The Company recognized an expense related to defined contribution plans of $4 million for the nine months ended September 30, 2025[91] - The balance of Accumulated Other Comprehensive Loss (AOCL) was $(441) million as of September 30, 2025, reflecting a change from $(472) million at December 31, 2024[93] - The Company believes it has recorded adequate provisions for various claims and litigation as of September 30, 2025, but the ultimate outcome remains unpredictable[94] - The Company had outstanding forward exchange contracts with gross notional values of $239 million as of September 30, 2025, with approximately 81% maturing within three months[81] - The fair value of the Company's long-term debt was estimated at $697 million as of September 30, 2025, compared to a fair value of $676 million as of December 31, 2024[88] - The Company had $546 million of outstanding surety bonds and $131 million of outstanding letters of credit as of September 30, 2025, to secure performance obligations[104]

Financial Performance - Q3 2025 revenue was $767 million, a decrease of 5.0% year-over-year from $807 million in Q3 2024[5] - Adjusted EBITDA for Q3 2025 was $40 million, representing a 25.0% increase compared to $32 million in Q3 2024[7] - Adjusted EBITDA margin improved to 5.2%, up 110 basis points from 4.1% in the prior year[5] - Revenue for Q3 2025 was $767 million, a decrease of 4.95% from $807 million in Q3 2024[20] - Adjusted Revenue for Q3 2025 was $767 million, down from $807 million in Q3 2024, reflecting a decrease of approximately 4.95%[47] - Adjusted Net Income for Q3 2025 was $(11) million, compared to $(24) million in Q3 2024, showing an improvement of 54.17%[47] - Adjusted Operating Income for Q3 2025 was $(8) million, compared to $(11) million in Q3 2024, reflecting an improvement of 27.27%[48] - Comprehensive loss for Q3 2025 was $50 million, compared to a comprehensive income of $137 million in Q3 2024[21] - Net loss for Q3 2025 was $46 million, compared to a net income of $123 million in Q3 2024, representing a significant decline[20] Cash Flow and Liquidity - Cash flow from operating activities was $(39) million, a decline of 200.0% compared to $(13) million in Q3 2024[5] - The company maintained a cash balance of $264 million and $198 million in unused capacity under its credit facility at the end of the quarter[6] - Cash and cash equivalents decreased to $248 million as of September 30, 2025, down from $366 million at the end of 2024[23] - Free Cash Flow for Q3 2025 was $(60) million, compared to $(29) million in Q3 2024, and for the nine months ended September 30, 2025, it was $(171) million versus $(153) million in 2024[50] - Operating Cash Flow for Q3 2025 was $(39) million, a decrease from $(13) million in Q3 2024, and for the nine months ended September 30, 2025, it was $(112) million compared to $(91) million in 2024[50] Business Operations and Strategy - New business signings for the quarter totaled $111 million in annual contract value (ACV)[4] - The company achieved 87% of its $1 billion capital allocation target to date, focusing on cash generation and expanding pipeline opportunities[3] - The company announced the integration of generative AI into government solutions to enhance service delivery and combat fraud[8] - Conduent expanded its operations in the Philippines with a new facility to support customer experience management solutions[10] - New Business Annual Contract Value (ACV) metrics indicate potential growth opportunities, although specific figures were not disclosed[26] Costs and Expenses - Total operating costs and expenses increased to $805 million in Q3 2025 from $648 million in Q3 2024, marking a rise of 24.2%[20] - The company reported a significant loss on divestitures and transaction costs, netting $1 million in Q3 2025 compared to a gain of $188 million in Q3 2024[20] - The company incurred transaction costs of $2 million in Q3 2025, down from $7 million in Q3 2024[50] - Direct response costs related to a cyber event amounted to $25 million in Q3 2025, which were not present in Q3 2024[48] - Direct response costs related to cyber event payments were $7 million in Q3 2025, with an additional $9 million incurred in the nine months ended September 30, 2025[50] Assets and Liabilities - Total assets decreased to $2.5 billion as of September 30, 2025, compared to $2.6 billion at the end of 2024[23] - Long-term debt increased to $697 million as of September 30, 2025, up from $615 million at the end of 2024[23] Taxation - Adjusted Effective Tax Rate for Q3 2025 was 44.7%, significantly higher than 12.5% in Q3 2024, while for the nine months ended September 30, 2025, it was 29.0% compared to 19.7% in 2024[49] - The effective tax rate for Q3 2025 was (19.5)%, compared to 22.2% in Q3 2024, indicating a significant shift in tax liabilities[49] - Adjusted Effective Tax Rate adjustments for Q3 2025 included $17 million, compared to $39 million in Q3 2024[47] Other Financial Metrics - Adjusted Diluted EPS for Q3 2025 was $(0.09), compared to $(0.14) in Q3 2024, while for the nine months ended September 30, 2025, it was $(0.34) compared to $(0.36) in 2024[49] - The company reported a loss before income taxes margin of (5.0)% for Q3 2025, compared to a profit margin of 19.7% in Q3 2024[49] - The company reported a loss on extinguishment of debt of $1 million in Q3 2025, consistent with the previous year[47] - The company experienced a goodwill impairment charge, which is part of the adjustments made to financial measures[37] - Total non-GAAP adjustments for Q3 2025 included a positive impact of 0.10 on Diluted EPS, while for the nine months ended September 30, 2025, it was 0.41[49]

Financial Performance - The net loss for the nine months ended September 30, 2025, was $3,326,457, compared to a net loss of $2,644,525 for the same period in 2024, indicating an increase in loss of about 26%[18]. - The comprehensive loss for the nine months ended September 30, 2025, was $3,153,186, compared to $2,690,565 in 2024, indicating an increase of about 17%[15]. - The Company reported a net loss of $732,303 for the three months ended September 30, 2025, compared to a net loss of $667,302 for the same period in 2024, indicating a year-over-year increase in losses[62]. - The Company expects to operate at a loss for the foreseeable future and will require additional financing to cover anticipated general and administrative costs[80]. Assets and Liabilities - As of September 30, 2025, total assets increased to $57,859,441 from $56,519,769 as of December 31, 2024, representing a growth of approximately 2.4%[14]. - Total liabilities increased to $300,438 from $177,477, reflecting a rise of approximately 69%[14]. - Shareholders' equity increased to $57,559,003 as of September 30, 2025, from $56,342,292 at the end of 2024, representing a growth of about 2.2%[14]. - The Company had a working capital of $2,176,414 as of September 30, 2025, compared to $959,703 at December 31, 2024, indicating improved liquidity[79]. Cash and Cash Equivalents - Cash and cash equivalents rose significantly to $2,277,809, up from $992,487, marking an increase of approximately 129%[18]. - As of September 30, 2025, the company had cash and cash equivalents of $2,277,809, an increase from $992,487 at December 31, 2024, indicating a significant improvement in liquidity[22]. Share Issuance and Compensation - The company issued 8,192,031 shares during the nine months ended September 30, 2025, raising $3,932,994 in share capital[17]. - The company issued 8,192,031 common shares during the nine months ended September 30, 2025, raising $3,932,994 through a non-brokered private placement at a price of $0.4801 per share[42]. - Stock-based compensation for options and DSUs totaled $558,807 for the nine months ended September 30, 2025, compared to $376,869 in 2024, reflecting an increase of approximately 48%[18]. - Share-based payment charges for the nine months ended September 30, 2025, totaled $558,807, an increase of $181,938 compared to $376,869 for the same period in 2024[73]. Mineral Property Activities - The total expenditures for mineral property activities for the nine months ended September 30, 2025 amounted to $1,165,757, compared to $878,456 for the same period in 2024, reflecting a year-over-year increase of approximately 32.7%[32]. - The company has a 100% interest in the Livengood Gold Project, with mineral property costs remaining unchanged at $55,375,124 as of September 30, 2025[30]. - The Livengood Gold Project has proven and probable reserves of 430.1 million tonnes at an average grade of 0.65 g/tonne, equating to approximately 9.0 million ounces of gold[57]. - Mineral property expenditures increased to $215,361 for the three months ended September 30, 2025, up from $119,401 in the same period of 2024, reflecting a rise of approximately 80.5%[63]. Financing and Future Operations - The company anticipates needing significant additional financing to continue operations and advance activities at the Livengood Gold Project, with substantial doubt about its ability to continue as a going concern[24]. - The Company anticipates expenditures of approximately $3.7 million for the year ending December 31, 2025, to be funded from cash on hand[84]. - The company is exploring strategic alliances to assist in further development and financing, although there is no assurance that such alliances will be realized[23]. Internal Controls and Compliance - As of September 30, 2025, the Company's disclosure controls and procedures were deemed effective by the Chief Executive Officer and Chief Financial Officer[88]. - There were no changes in internal control over financial reporting during the quarter ended September 30, 2025, that materially affected the Company's internal control[90]. - The Company and its subsidiaries were not subject to regulation by MSHA under the Mine Act during the nine months ended September 30, 2025[96]. Other Financial Information - The average exchange rate during the three months ended September 30, 2025, was C$1 to $0.7261, compared to C$1 to $0.7332 during the same period in 2024, reflecting a slight strengthening of the U.S. dollar[69]. - The company has unrecognized compensation expense of C$282,780 related to non-vested options, expected to be recognized over approximately 1.2 years[46]. - The weighted average remaining life of options outstanding at September 30, 2025, was 2.0 years[44]. - The expected life of options is 6 years, with an annualized volatility of 78.48% as of September 30, 2025[53]. - The company has contractual obligations totaling $4,808,412 related to mineral property payments due by year, including $165,790 in 2025[55]. - The company has paid a total of $610,457 in minimum royalties related to the Alaska Mental Health Trust lease during the nine months ended September 30, 2025[34]. - As of September 30, 2025, the company had 3,455,000 stock options outstanding with a weighted average exercise price of C$0.79, representing an intrinsic value of C$5,150,800[44]. - During the nine months ended September 30, 2025, the company granted 240,000 stock options and 332,000 Deferred Share Units (DSUs), with total share-based payment compensation amounting to $558,807[51]. - The company has no revenue-generating operations, which limits its ability to internally generate funds[22]. - No director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" during the three months ended September 30, 2025[97]. - The Company has been classified as a "passive foreign investment company" (PFIC) for U.S. federal income tax purposes and expects to maintain this status in the future[87].

Financial Performance - AAM's sales for Q3 2025 were $1.51 billion, a slight increase from $1.50 billion in Q3 2024[5] - Net income for Q3 2025 was $9.2 million, or 0.6% of sales, compared to $10.0 million, or 0.7% of sales in Q3 2024[6] - Adjusted EBITDA for Q3 2025 was $194.7 million, representing 12.9% of sales, up from $174.4 million, or 11.6% of sales in Q3 2024[7] - Adjusted free cash flow for Q3 2025 was $98.1 million, an increase from $74.6 million in Q3 2024[8] - Net sales for Q3 2025 were $1,505.3 million, slightly up from $1,504.9 million in Q3 2024, while net sales for the nine months ended September 30, 2025, decreased to $4,452.8 million from $4,744.1 million in the same period of 2024[26] - Gross profit for Q3 2025 increased to $189.0 million, compared to $171.3 million in Q3 2024, while gross profit for the nine months ended September 30, 2025, decreased to $563.6 million from $587.1 million in 2024[26] - Operating income for Q3 2025 was $48.4 million, up from $41.7 million in Q3 2024, but down from $146.1 million for the nine months ended September 30, 2025, compared to $205.2 million in 2024[26] - Net income for Q3 2025 was $9.2 million, a slight decrease from $10.0 million in Q3 2024, while net income for the nine months ended September 30, 2025, increased to $55.6 million from $48.7 million in 2024[26] - Adjusted EBITDA for Q3 2025 was $194.7 million, compared to $174.4 million in Q3 2024, while for the nine months ended September 30, 2025, it decreased to $574.2 million from $588.4 million in 2024[32] - Free cash flow for Q3 2025 was $79.5 million, up from $70.7 million in Q3 2024, while for the nine months ended September 30, 2025, it decreased to $105.7 million from $139.8 million in 2024[37] Financial Outlook - AAM's updated financial outlook for FY 2025 targets sales between $5.8 billion and $5.9 billion, up from the previous range of $5.75 billion to $5.95 billion[18] - The company is targeting Adjusted EBITDA in the range of $710 million to $745 million for FY 2025, compared to the prior range of $695 million to $745 million[18] - AAM expects Adjusted free cash flow for FY 2025 to be between $180 million and $210 million, slightly adjusted from the previous range of $175 million to $215 million[18] - The company targets full year 2025 adjusted EBITDA in the range of $710 million to $745 million, indicating a focus on improving operational efficiency[42] - Full year 2025 targeted free cash flow is projected to be between $115 million and $145 million, highlighting the company's cash generation capabilities[42] - Adjusted free cash flow for 2025 is expected to be between $180 million and $210 million, reflecting the company's commitment to managing cash flow effectively[42] Asset and Liability Management - Total assets as of September 30, 2025, increased to $5,343.2 million from $5,059.9 million as of December 31, 2024[28] - Total liabilities as of September 30, 2025, rose to $4,624.8 million from $4,497.1 million as of December 31, 2024[28] - Cash and cash equivalents at the end of Q3 2025 were $714.1 million, an increase from $552.9 million at the end of 2024[28] Segment Performance - Driveline segment sales for Q3 2025 were $1,051.1 million, a slight increase from $1,042.8 million in Q3 2024, while Metal Forming segment sales decreased to $595.0 million from $596.5 million[39] - Segment adjusted EBITDA for the Driveline segment was $156.8 million in Q3 2025, up from $135.7 million in Q3 2024, indicating strong performance in this area[39] - Total segment adjusted EBITDA for Q3 2025 was $194.7 million, compared to $174.4 million in Q3 2024, representing an increase of about 11.8%[39] Strategic Initiatives - AAM continues to progress towards its combination with Dowlais, enhancing its position as a global supplier[5] - The company emphasizes the importance of non-GAAP financial measures for operational planning and decision-making[13] - The company is focused on strategic initiatives to enhance market position and operational performance, including ongoing investments in new technologies and market expansion efforts[42] Restructuring and Costs - The company reported restructuring-related costs of $45 million and acquisition-related costs of $55 million for the full year 2025, which will impact overall profitability[42] Sales Trends - The company experienced a decline in total sales for the nine months ended September 30, 2025, with total sales of $4,860.2 million compared to $5,167.4 million in 2024, a decrease of approximately 5.9%[39] - Total net external sales for the nine months ended September 30, 2025, were $4,452.8 million, down from $4,744.1 million in the same period of 2024, reflecting a decrease of approximately 6.1%[39]

NEWS RELEASE Exhibit 99.1 Gray Media Beats Guidance With Strong Third Quarter Financial Results Atlanta, Georgia – November 7, 2025. . . Gray Media, Inc. ("Gray," "Gray Media," "we," "us" or "our") (NYSE: GTN) today announced its financial results for the quarter ended September 30, 2025. We are pleased to report that our total revenue, core advertising revenue, retransmission revenue, and political advertising revenue all were at or exceeded the high-end of our previously issued guidance ranges for the qua ...